Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy

Graefes Arch Clin Exp Ophthalmol. 2023 Aug;261(8):2235-2243. doi: 10.1007/s00417-023-06030-3. Epub 2023 Mar 8.

Abstract

Purpose: To assess the effects of half-dose photodynamic therapy (PDT) combined with an intravitreous aflibercept (IVA) injection for pachychoroid neovasculopathy (PNV) and its predictive factors.

Methods: Clinical information of 43 patients (43 eyes) with PNV obtained before and 6 months after treatment with half-dose PDT combined with IVA was retrospectively analyzed. Patients were categorized into the sufficient (25 eyes, 58.1%) or insufficient (18 eyes, 41.9%) group based on resolution or persistence/recurrence of subretinal fluid (SRF), respectively, and clinical data were compared. Macular neovascularization (MNV) change was studied in 30 cases with available pre- and post-treatment optical coherence tomography angiography images.

Results: The sufficient group included younger patients with better baseline best-corrected visual acuity (BCVA), more treatment-naïve eyes, and smaller MNV lesions at baseline than the insufficient group (all, P < 0.047). Complete SRF resolution was 81.8% in treatment-naïve eyes and only 33.3% in previously treated eyes. MNV expanded after half-dose PDT was combined with IVA regardless of the treatment outcome (P = 0.003).

Conclusion: Half-dose PDT combined with IVA was effective for PNV treatment, especially for younger patients with good baseline BCVA, treatment-naïve eyes, and small MNV sizes at baseline. MNV expanded after treatment regardless of the treatment outcomes.

Keywords: Half-dose photodynamic therapy; Macular neovascularization; Optical coherence tomography angiography; Pachychoroid disease; Pachychoroid neovasculopathy.

MeSH terms

  • Fluorescein Angiography / methods
  • Fundus Oculi
  • Humans
  • Photochemotherapy* / methods
  • Receptors, Vascular Endothelial Growth Factor*
  • Retrospective Studies
  • Tomography, Optical Coherence

Substances

  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor